ACCESSIBILITY

24/7

Headlines

14:09

What made Q.ai worth $1.5 billion to Apple

11:25

Why Apple paid billions for a company with no revenue

10:29

The next phase of innovation: Mind the Tech Week NY 2026

21:26

“We sped research that should have taken 20 years”: Inside Q.ai’s Apple exit

Buzz

Most popular

Daily

Weekly

“A Great Depression-scale recession is coming by the end of the decade”

Israel orders $183 million in air-to-ground bombs from Elbit

Apple acquires secretive Israeli AI startup Q.ai for $1.5 billion

“SaaS is dying as a business category”

Tower Semiconductor surges to $15 billion valuation, tripling Intel’s abandoned bid

More news

FDA

18 stories about FDA

Teva Shares Rise Following FDA Approval of Migraine Drug

16.09.18|Dror Reich

Teva’s new migraine drug is forecasted to bring in $500 million in sales annually

FDA Approves Brainsway’s Magnetic Stimulation Headset for OCD Treatment

19.08.18|CTech

Brainsway develops non-invasive medical devices that are worn on the head like helmets to apply magnetic stimulation to treat brain disorders

Teva Wins FDA Approval for First Generic EpiPen

19.08.18|Lilach Baumer

EpiPens were sold for less than $60 when Mylan acquired the injectors in 2007. Market Monopoly enabled the company to hike its price up to around $300 a unit today

Medical Analytics Company DiA Imaging Raises $5 Million

08.08.18|CTech

DiA develops a medical imaging analysis software based on pattern recognition and machine learning algorithms

Mobile Phone Urine Testing Kit Receives FDA Approval

26.07.18|Tofi Stoler

Developed by Tel Aviv-based Healthy.io, the technology uses computer vision algorithms, artificial intelligence, and a smartphone’s built-in camera to run lab-standard urine tests

Kleiner Perkins, Alphabet Back Stroke Detection Startup Viz.ai

18.07.18|Meir Orbach

Kleiner Perkins led a $21 million round for the medical startup. Viz.ai develops an automated analysis of brain scans

זקן כיסא גלגלים ביטוח בריאות ביטוח סיעודי

Following FDA Clearance, BioSight to Launch Clinical Trial for Treatment of Leukemia

15.07.18|CTech

The company’s compound will be administered to patients unfit for standard chemotherapy

Sustained Drug Release Company UroGen Submits New Drug Application to FDA

12.07.18|Amir Rosenbaum

Kite Pharma founder Arie Belldegrun is the chairman of Israel-based UroGen, which focuses mainly on cancer treatment and urinary tract infections

MediWound’s Pineapple-Based Burn Treatment to Treat Mustard Gas Burns

31.05.18|Dror Reich

The Nasdaq-listed, Israeli based company received the FDA’s approval to expand the use of flagship burn treatment NexoBrid to those suffering from Sulfur Mustard injuries

CTech's Tuesday Roundup of Israeli Tech News

24.04.18|CTech

The challenges of living on Mars: air, water, lack of personal space. Israeli lawmaker’s Twitter account suspended after tweet saying Palestinian girl in custody should have been shot

AI Healthcare Company Viz.ai Receives FDA Clearance for Stroke Detection Technology

23.04.18|Hagar Ravet

Viz.ai develops deep learning and AI-powered technology that can analyze brain scans and automatically transfer pertinent data to a physician to ensure the most immediate treatment for strokes

ReWalk Launches Clinical Trials for Robotic Physical Rehab Suit

04.04.18|Asaf Shalev

After the conclusion of the 40-person trial, the company will seek clearance from U.S. and European regulators

Israeli Telehealth Startup Tyto Care Raises $21 Million

28.01.18|Meir Orbach

Tyto Care develops a digital stethoscope for remote medical testing and diagnosis

Kite Pharma’s Cancer Drug Gets Regulatory Nod

19.10.17|Lilach Baumer

The cancer-treatment company, bought by Gilead Science in August for $11.9 billion, will sell one treatment course of the drug for $373,000

Teva Submits Potential Moneymaker Migraine Drug for FDA Approval

18.10.17|Dror Reich and Lilach Baumer

Teva’s patent for its moneymaker multiple sclerosis drug Copaxone expired last year

Teva’s Stock Drops After Approval of Copaxone Competitors

08.10.17|Lilach Baumer

A day after Mylan announced FDA approval for its generic versions of Copaxone, drug companies Synthon and Alvogen announce European approval for their 40 mg/ml generic versions of Teva's blockbuster drug

Teva Loses Copaxone Market Exclusivity

04.10.17|Lilach Baumer

Rival Mylan received FDA approval for its generic versions of Copaxone, Teva’s flagship drug

Developer Of Anti-Rabies Drug Jumps on FDA Approval

27.08.17|Dror Reich

The plasma-derived drug is used together with the rabies vaccine to treat unvaccinated persons exposed to the virus